SCHEMBL24935669

SCHEMBL24935669

CC(C)C(=O)COCCCCOc1ccc(C(C)C)c(C(F)(F)F)c1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
THRA P10827 1/20 0.41
THRB P10828 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
PPARG P37231 2/20 0.37
PPARA Q07869 2/20 0.37
PTGES O14684 1/20 0.37
ALOX5 P09917 1/20 0.37
SRD5A2 P31213 1/20 0.36
NOTUM Q6P988 1/20 0.36
RORC P51449 1/20 0.35
CARM1 Q86X55 1/20 0.35
S1PR1 P21453 1/20 0.35
PPARD Q03181 1/20 0.35
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25063888 0.86 KDM4E (0.36) THRATHRBPPARGPPARAPTGES
SCHEMBL25063890 0.85 PPARG (0.38) THRATHRBPPARGPPARAPTGES
SCHEMBL24935466 0.84 CARM1 (0.40) HDAC1HDAC2PPARGCARM1PPARD
SCHEMBL25063751 0.84 S1PR1 (0.36) THRATHRBSRD5A2NOTUMRORC
SCHEMBL5514977 0.78 AGER (0.51) THRATHRBPPARASRD5A2PPARD
SCHEMBL24935185 0.75 KMT2A (0.50) HDAC1HDAC2
SCHEMBL21725512 0.74 NQO1 (0.43) NOTUMRORCCYP2C19
SCHEMBL25063880 0.74 KMT2A (0.41) PPARGRORCCARM1PPARDCYP1A2
SCHEMBL24935357 0.73 HDAC1 (0.44) THRATHRBHDAC1HDAC2PPARG
SCHEMBL21982857 0.71 TSHR (0.55) CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230054270-A1 BIFUNCTIONAL COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) 2023-02-23 US disclosed
EP-4119546-A1 BIFUNCTIONAL COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF Suzhou Kintor Pharmaceuticals, Inc. (CN) 2023-01-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230054270-A1 BIFUNCTIONAL COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF AR, SHBG, NR5A1 THRA 1995/4885THRB 1512/4885HDAC1 1454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.